Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer, D. W. Dodick, Q. Zhang, J. N. Carter, J. Ailani, R. R. Conley

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

Original languageEnglish (US)
Pages (from-to)872
Number of pages1
JournalJAMA neurology
Volume76
Issue number7
DOIs
StatePublished - Jul 2019

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)'. Together they form a unique fingerprint.

Cite this